Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.

Autor: Borel C; Institut de Cancérologie Strasbourg Europe, Strasbourg, France. Electronic address: c.borel@icans.eu., Sun XS; Hôpital Nord Franche-Comté, Montbéliard, France; Centre Hospitalo-Universitaire Besançon, Besançon, France., Coutte A; Centre Hospitalo-Universitaire Amiens-Picardie-Site Sud, Amiens, France., Bera G; Centre Hospitalier Bretagne Sud, Lorient, France., Sire C; Centre Hospitalier Bretagne Sud, Lorient, France., Zanetta S; Centre Georges-François Leclerc, Dijon, France., Alfonsi M; Institut Sainte Catherine, Avignon, France., Janoray G; Centre Hospitalier Régional Universitaire Tours, Tours, France., Chatellier T; Centre d'Oncologie de l'Estuaire, Saint-Nazaire, France., Garcia-Ramirez M; Hôpital Robert Boulin, Libourne, France., Gherga E; Hôpital Nord Franche-Comté, Montbéliard, France., Hammoud Y; Centre Hospitalo-Universitaire Besançon, Besançon, France., Burgy M; Institut de Cancérologie Strasbourg Europe, Strasbourg, France; Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, Illkirch, France., Etienne-Selloum N; Institut de Cancérologie Strasbourg Europe, Strasbourg, France; Laboratory of Bioimaging and Pathology, University of Strasbourg, UMR7021 CNRS, Illkirch, France., Pechery A; Groupe d'Oncologie Radiothérapie Tête Et Cou (GORTEC) - Centre Hospitalo-Universitaire Bretonneau, Tours, France., Girard-Calais MH; Groupe d'Oncologie Radiothérapie Tête Et Cou (GORTEC) - Centre Hospitalo-Universitaire Bretonneau, Tours, France., Velten M; Institut de Cancérologie Strasbourg Europe, Strasbourg, France; Université de Strasbourg, UMR-S1113 IRFAC Inserm, Strasbourg, France., Pignon JP; Service de Biostatistique et d'Epidémiologie, Gustave-Roussy Cancer Campus, Villejuif, France., Wanneveich M; Groupe d'Oncologie Radiothérapie Tête Et Cou (GORTEC) - Centre Hospitalo-Universitaire Bretonneau, Tours, France., Bourhis J; CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Jazyk: angličtina
Zdroj: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Aug; Vol. 197, pp. 110329. Date of Electronic Publication: 2024 May 19.
DOI: 10.1016/j.radonc.2024.110329
Abstrakt: Background: Chemoradiotherapy with high-dose cisplatin (HD-Cis: 100 mg/m 2 q3w for three cycles) is the standard of care (SOC) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Cumulative delivered dose of cisplatin is prognostic of survival, even beyond 200 mg/m 2 but high toxicity compromises its delivery.
Aim: Cisplatin fractionation may allow, by decreasing the peak serum concentration, to decrease toxicity. To date, no direct comparison was done of HD-Cis versus fractionated high dose cisplatin (FHD-Cis).
Methods: This is a multi-institutional randomized phase II trial, stratified on postoperative or definitive chemoradiotherapy, comparing HD-Cis to FHD-Cis (25 mg/m 2 /d d1-4 q3w for 3 cycles) in patients with LA-HNSCC. The primary endpoint was the cumulative delivered cisplatin dose.
Results: Between December 2015 and April 2018, 124 patients were randomized. Median cisplatin cumulative delivered dose was 291 mg/m 2 (IQR: 251;298) in the FHD-Cis arm and 274 mg/m 2 (IQR: 198;295) in the HD-Cis arm (P = 0.054). The proportion of patients receiving a third cycle of cisplatin was higher, with a lower proportion of grade 3-4 acute AEs in the FHD-Cis arm compared to the HD-Cis arm: 81 % vs. 64 % (P = 0.04) and 10 % vs. 17 % (P = 0.002), respectively. With a median follow-up of 48 months (IQR: 41;55), locoregional failure rate, PFS and OS were similar between the two arms.
Conclusion: Although the primary endpoint was not met, FHD-Cis allowed more cycles of cisplatin to be delivered with lower toxicity, when compared to SOC. FHD-Cis concurrently with RT is a treatment option which deserves further consideration.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: